Target Virus or Target Ourselves for COVID-19 Drugs Discovery?―Lessons learned from anti-influenza virus therapies | Zendy

Jiayu Liao | Zendy; George Way | Zendy; Vipul Madahar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Target Virus or Target Ourselves for COVID-19 Drugs Discovery?―Lessons learned from anti-influenza virus therapies

Author(s) -

Jiayu Liao,

George Way,

Vipul Madahar

Publication year - 2020

Publication title -

medicine in drug discovery

Language(s) - English

Resource type - Journals

ISSN - 2590-0986

DOI - 10.1016/j.medidd.2020.100037

Subject(s) - pandemic , covid-19 , hydroxychloroquine , virology , medicine , coronavirus , public health , drug repositioning , intensive care medicine , drug , pharmacology , infectious disease (medical specialty) , outbreak , pathology , disease

The COVID-19 pandemic, after it was reported in December 2019, is a highly contagious and now spreading to over 190 countries, causing a severe public health burden. Currently, there is no vaccine or specific drug to treat COVID-19, which is caused by a novel coronavirus, SARS-2-CoV. For this emergency, the FDA has approved Remdesivir and Hydroxychloroquine for treatment of COVID-19 as Emergency Use Authorization. However, even after this pandemic, COVID-19 may still have a chance to come back. Therefore, we need to come out with new strategies for drug discovery for combating COVID-19 in the future.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research